Eisai’s regulatory progress brings cash flow for BioArctic

Yesterday, the Japanese pharmaceutical giant Eisai announced that Leqembi has been approved in Japan. The intravenous infusion treatment has been given the green light as a treatment to slow the progression of mild cognitive impairment and mild dementia caused by Alzheimer’s disease. The approval entails a milestone payment to the Swedish biotech company BioArctic of EUR 17 million.

Read the article at biostock.se:

https://www.biostock.se/en/2023/09/eisais-regulatory-progress-brings-cash-flow-for-bioarctic/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/